soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Oral Semaglutide Cuts Cardiovascular Risk

Research published in the New England Journal of Medicine (NEJM), shows that over a 40-week trial participants taking orforglipron reduced their glycated haemoglobin levels significantly more than those on a placebo

Trulicity is available at Vitercure through licensed clinicians who review your medical history before issuing a prescription

Lemon Balm - 100 mg of 10:1 extract - traditionally used to ease nervous tension

Most studies on humans are using dosages between 250 and 500 mg per day so this is above that

Most of the studies were designed to evaluate cardiovascular or renal outcomes, with diabetic retinopathy data collected through inconsistent and variably rigorous adverse events reporting

Lowering the dose could reduce side effects while still managing your condition effectively